Jacobs Levy Equity Management’s Arcturus Therapeutics ARCT Stock Holding History

Jacobs Levy Equity Management’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.35M	Buy	647,511 +448,783	+226%	+$3.54M	0.02%	456
2026 Q1	$1.53M	Sell	198,728 -94,322	-32%	-$688K	0.01%	630
2025 Q4	$1.8M	Sell	293,050 -12,609	-4%	-$136K	0.01%	599
2025 Q3	$5.63M	Sell	305,659 -189,632	-38%	-$3.05M	0.02%	405
2025 Q2	$6.44M	Buy	495,291 +351,150	+244%	+$4.15M	0.03%	381
2025 Q1	$1.53M	Buy	144,141 +24,583	+21%	+$390K	0.01%	720
2024 Q4	$2.03M	Buy	119,558 +19,859	+20%	+$374K	0.01%	587
2024 Q3	$2.31M	Sell	99,699 -637	-0.6%	-$13.6K	0.01%	575
2024 Q2	$2.44M	Buy	100,336 +4,412	+5%	+$134K	0.01%	571
2024 Q1	$3.24M	Buy	95,924 +50,470	+111%	+$1.79M	0.01%	507
2023 Q4	$1.43M	Buy	45,454 +36,128	+387%	+$859K	0.01%	660
2023 Q3	$238K	Sell	9,326 -7,912	-46%	-$244K	﹤0.01%	906
2023 Q2	$494K	Buy	+17,238	New	+$469K	﹤0.01%	826

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Jacobs Levy Equity Management's ARCT Position: Q2 2026 in Review

Jacobs Levy Equity Management increased its Arcturus Therapeutics (ARCT) stake by 226% in Q2 2026, buying an estimated $3.54M and bringing the position to 647,511 shares worth $4.35M. The position accounts for 0.02% of the portfolio, ranked #456.

Jacobs Levy Equity Management first reported a position in ARCT in Q2 2023 and has held it in 13 quarters since. The position peaked at $6.44M in Q2 2025. 135 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

Jacobs Levy Equity Management held 647,511 shares of Arcturus Therapeutics worth $4.35M as of Q2 2026.
Jacobs Levy Equity Management bought 448,783 Arcturus Therapeutics shares in Q2 2026, an estimated $3.54M.
Arcturus Therapeutics made up 0.02% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #456 holding.
Jacobs Levy Equity Management first reported a position in Arcturus Therapeutics in Q2 2023 and has held it in 13 quarters since.
Jacobs Levy Equity Management's Arcturus Therapeutics position peaked at $6.44M in Q2 2025.
135 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.